CELYAD SA/ADR (CYAD) Reaches New 12-Month Low at $20.58
CELYAD SA/ADR (NASDAQ:CYAD)’s share price hit a new 52-week low during mid-day trading on Thursday . The stock traded as low as $20.58 and last traded at $20.88, with a volume of 682 shares trading hands. The stock had previously closed at $24.75.
Several equities analysts have issued reports on CYAD shares. William Blair restated a “buy” rating on shares of CELYAD SA/ADR in a research report on Tuesday. HC Wainwright restated a “buy” rating and issued a $46.00 price target on shares of CELYAD SA/ADR in a research report on Wednesday, November 21st. Zacks Investment Research upgraded shares of CELYAD SA/ADR from a “hold” rating to a “buy” rating and set a $31.00 price objective for the company in a research report on Thursday, November 15th. Finally, Piper Jaffray Companies decreased their price objective on shares of CELYAD SA/ADR to $51.00 and set an “overweight” rating for the company in a research report on Monday, November 12th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $44.20.
The stock has a market capitalization of $210.28 million, a price-to-earnings ratio of -6.61 and a beta of 1.35.
CELYAD SA/ADR Company Profile (NASDAQ:CYAD)
Celyad SA, a clinical-stage biopharmaceutical company, focuses on the development of CAR-T cell-based therapies. The company utilizes its expertise in cell engineering to target cancer. Its CAR-T cell platform has the potential to treats a range of solid and hematologic tumors. The company's lead drug product candidate, CYAD-01 (CAR-T NKG2D), has been evaluated in a Phase I clinical trial to assess the safety and clinical activity of multiple administrations of autologous CYAD-01 cells in seven refractory cancers, including five solid tumors, such as colorectal, ovarian, bladder, triple-negative breast, and pancreatic cancers; and two hematological tumors comprising acute myeloid leukemia and multiple myeloma.
Featured Story: What kind of dividend yield to CEF’s pay?
Receive News & Ratings for CELYAD SA/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CELYAD SA/ADR and related companies with MarketBeat.com's FREE daily email newsletter.